This website uses cookies to ensure that we give you the best experience on our website. Click here for more information.


Terms of Use

The information contained in this site is for healthcare professionals only.

I am not a healthcare professional I confirm to be a healthcare professional
About Prolia®

Osteoporosis treatment with Prolia® (denosumab)

Prolia® (denosumab) is a medicine for the treatment of osteoporosis. It is used in postmenopausal women and in men with osteoporosis and at increased risk of fracture or receiving hormonal ablation therapy for prostate cancer. By reducing bone loss, increasing bone density or maintaining bone strength, Prolia® (denosumab) reduces the risk of osteoporotic fractures.

Several clinical studies have demonstrated that Prolia® (denosumab) helps to strengthen bone tissue and significantly reduce fracture risk. In the pivotal study of Prolia® that evaluated denosumab in men ≥ 70 years of age with histologically confirmed prostate cancer, or men < 70 years of age with histologically confirmed prostate cancer and a history of osteoporotic fracture or low BMD T-score at the lumbar spine, total hip, or femoral neck, the efficacy was shown as vertebral fracture incidence reduction as well as bone density gains in the lumbar spine (lower spine).

Therapeutic indications of Prolia® (denosumab)

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Prolia® significantly reduces the risk of vertebral, non-vertebral and hip fractures. Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, Prolia® significantly reduces the risk of vertebral fractures.

Prolia® Mechanism of Action

Prolia® (denosumab) is a first in class therapy with a mechanism of action that improves bone strength and reduces bone loss.

learn more

Clinical Studies of Prolia®

Several clinical studies have been conducted to assess the efficacy of Prolia® (denosumab) in reducing osteoporotic fracture risk in male and female patients. 

learn more

Benefits of Prolia®

Clinical studies have demonstrated that Prolia® (denosumab) is effective in lowering the risk of fragility fractures associated with osteoporosis.

learn more

Find the information you need to prescribe Prolia® (denosumab) to your patients

Download relevant resources here.